ZEOXOTCBiological Products, (No Diagnostic Substances)US GAAP · USD

Zeo ScientifiX, Inc.

Zeo ScientifiX, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on biological therapeutics for degenerative diseases and regenerative medicine. Its portfolio includes products derived from ethically sourced birth tissue, amniotic fluid, exosomes, Wharton's Jelly matrix, and an autologous biologic platform, with operations centered on manufacturing, commercialization, and related clinical support services.

Kysy yhtiöstä
Liikevaihto5,2milj. USD
+12,5 %v/v
Liikevoitto (EBIT)−5,4milj. USD
−1,3 %v/v
EBIT-marginaali−103,6%
+11,5 %-yks.v/v
Nettotulos−5,5milj. USD
−17,3 %v/v
Vapaa kassavirta−0,7milj. USD
+0,0 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−15−10−50510milj. USD2020: 3,1 milj. USD2020: EBIT −12 milj. USD20202021: 5,6 milj. USD2021: EBIT −13 milj. USD20212022: 6,5 milj. USD2022: EBIT −8,8 milj. USD20222023: 4,6 milj. USD2023: EBIT −6,8 milj. USD20232024: 4,6 milj. USD2024: EBIT −5,3 milj. USD20242025: 5,2 milj. USD2025: EBIT −5,4 milj. USD20255,2−5,4
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Zeo ScientifiX, Inc.

Liiketoiminta

Osuus liikevaihdosta
Biologic therapeutics69 %

Proprietary biologic products derived from birth tissue, amniotic fluid, and related sources.

Autologous biologic services29 %

Patient-specific PPX™ processing and service platform using a patient's own blood.

Manufacturing and quality services2 %

cGMP production, release testing, and related laboratory support for biologic products.

Asiakkaat

Zeo ScientifiX sells primarily to healthcare providers, including doctors and clinics that administer regenerative medicine and aesthetic biologic products. Its commercial model also depends on distributors and, in collaboration settings, clinical and manufacturing partners that support product access and delivery.

Healthcare providers

Doctors, clinics, and treatment centers that purchase biologics for in-office use and patient care.

Regenerative medicine practices

Providers focused on degenerative disease, wound care, pain, and regenerative applications.

Aesthetic medicine providers

Clinics using allogenic aesthetic biologic products for cosmetic and related procedures.

Independent distributors

Channel partners that market and distribute the company's products to providers.

Clinical collaboration partners

Partners involved in manufacturing, regulatory development, and site management for specific programs.

Strategia

Zeo ScientifiX is focused on expanding commercialization of its biologic portfolio while continuing product development and clinical work in regenerative medicine. The company also appears to be building channel reach through in-house sales, distributors, and collaboration-based manufacturing and market-access arrangements.

Expand provider commercializationLyhyt aikaväli

The business depends on provider adoption and repeat use of its biologic products.

Develop new biologic offeringsKeskipitkä aikaväli

New products can broaden the addressable market and reduce reliance on a narrow product mix.

Strengthen collaboration-based executionKeskipitkä aikaväli

Partnerships can provide manufacturing capacity, regulatory support, and commercial reach.

Maantiede

The company is headquartered in Davie, Florida and operates through U.S.-based laboratory and commercial activities. Its disclosures indicate a customer and distribution network across the United States, with additional worldwide reach through its broader provider base and collaboration activity.

Riskit

The company faces substantial going-concern, funding, and execution risk because its business requires ongoing capital, regulatory compliance, and successful commercialization of biologic products. It also operates in a competitive and highly regulated regenerative medicine market where product acceptance, intellectual property protection, and supply continuity can materially affect results.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Going-concern and financing dependence1Regulatory and compliance risk2Competitive pressure3Internal control weaknesses4Supply concentration and third-party dependence5Intellectual property protection6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Going-concern and financing dependenceVaikutus: KriittinenTodennäköisyys: Korkea

    Operations and development require additional capital, and funding may be costly or unavailable.

    Kohdistuu: Corporate liquidity and ongoing operations

  2. Regulatory and compliance riskVaikutus: KorkeaTodennäköisyys: Korkea

    Products are biologics subject to FDA oversight, HCT/P enforcement, and cGMP requirements.

    KohdistuuProduct approvalCommercializationManufacturing
  3. Competitive pressureVaikutus: KorkeaTodennäköisyys: Korkea

    Larger competitors may have stronger brands, capital, and distribution, pressuring pricing and share.

    Kohdistuu: Allogenic biologics and regenerative medicine products

  4. Internal control weaknessesVaikutus: KorkeaTodennäköisyys: Korkea

    Material weaknesses can impair financial reporting reliability and investor confidence.

    Kohdistuu: Financial statements and disclosure controls

  5. Supply concentration and third-party dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Raw materials and supplies are sourced from unaffiliated laboratories and could be disrupted.

    Kohdistuu: Manufacturing continuity and product availability

  6. Intellectual property protectionVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Commercial success depends on patents and proprietary processing techniques.

    KohdistuuZofin™PPX™Related biologic platforms
Kysy Clarifolta: Zeo ScientifiX, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition by product vs. service

PPX™ service revenue and product sales may be recognized differently and shift period results.

Vaikutus: Affects revenue timing, gross margin, and comparability

Stock-based compensation

Reported G&A includes significant non-cash compensation to advisors, consultants, and staff.

Vaikutus: Can materially increase operating expenses

Going-concern and asset recoverability

Management's assumptions affect whether recorded assets are recoverable.

Vaikutus: May lead to impairment or write-down risk

Internal control and disclosure estimates

Material weaknesses increase the risk of misstatement in estimates and reported balances.

Vaikutus: Affects reliability of financial statements

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Zivo Bioscience, Inc.

ZIVO · Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

MiMedx Group, Inc

MDXG · Surgical & Medical Instruments & Apparatus

eXoZymes Inc

EXOZ · Biological Products, (No Diagnostic Substances)

Xenetic Biosciences, Inc.

XBIO · Pharmaceutical Preparations

Sangamo Therapeutics, Inc

SGMOQ · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026